Details for Patent: 7,465,465
✉ Email this page to a colleague
Which drugs does patent 7,465,465 protect, and when does it expire?
Patent 7,465,465 protects FOSRENOL and is included in two NDAs.
This patent has seventy-six patent family members in thirty-one countries.
Summary for Patent: 7,465,465
| Title: | Pharmaceutical formulation comprising lanthanum compounds |
| Abstract: | This invention relates to a chewable lanthanum formulation comprising a pharmaceutically effective amount of a lanthanum compound; and at least one chewable pharmaceutically acceptable excipient. This invention also relates to a pharmaceutical formulation in a tablet or in a powder comprising a pharmaceutically effective amount of a lanthanum compound produced by a process which comprises the steps of: a) powder blending the lanthanum compound and at least one pharmaceutically acceptable excipient in a mixer to form a mixture; or b) powder blending the lanthanum compound and excipients, compressing the resulting combination into a slug material or roller compacting the resulting combination into a strand material, and milling the prepared material into a free flowing mixture; and c) compressing the resulting mixture into a tablet or filing up the resulting mixture in a appropriate container. |
| Inventor(s): | Haslam; Robert Paul (Pewsey, GB), Trespidi; Laura Anna (Pizzighettone, IT), Ferdinando; Josephine Christine (Tadley, GB) |
| Assignee: | Shire Biochem Inc. (Laval, Quebec, CA) |
| Application Number: | 10/926,330 |
| Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for patent 7,465,465 |
|
Patent Claim Types: see list of patent claims | Composition; Formulation; Compound; Dosage form; Process; Use; |
Drugs Protected by US Patent 7,465,465
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Takeda Pharms Usa | FOSRENOL | lanthanum carbonate | POWDER;ORAL | 204734-002 | Sep 24, 2014 | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | Y | ⤷ Try a Trial | ||||
| Takeda Pharms Usa | FOSRENOL | lanthanum carbonate | POWDER;ORAL | 204734-001 | Sep 24, 2014 | RX | Yes | No | ⤷ Try a Trial | ⤷ Try a Trial | Y | ⤷ Try a Trial | ||||
| Takeda Pharms Usa | FOSRENOL | lanthanum carbonate | TABLET, CHEWABLE;ORAL | 021468-004 | Nov 23, 2005 | AB | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | Y | ⤷ Try a Trial | |||
| Takeda Pharms Usa | FOSRENOL | lanthanum carbonate | TABLET, CHEWABLE;ORAL | 021468-001 | Oct 26, 2004 | DISCN | No | No | ⤷ Try a Trial | ⤷ Try a Trial | Y | ⤷ Try a Trial | ||||
| Takeda Pharms Usa | FOSRENOL | lanthanum carbonate | TABLET, CHEWABLE;ORAL | 021468-002 | Oct 26, 2004 | AB | RX | Yes | No | ⤷ Try a Trial | ⤷ Try a Trial | Y | ⤷ Try a Trial | |||
| Takeda Pharms Usa | FOSRENOL | lanthanum carbonate | TABLET, CHEWABLE;ORAL | 021468-003 | Nov 23, 2005 | AB | RX | Yes | No | ⤷ Try a Trial | ⤷ Try a Trial | Y | ⤷ Try a Trial | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
International Family Members for US Patent 7,465,465
| Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
|---|---|---|---|---|---|
| Argentina | 056609 | ⤷ Try a Trial | |||
| Austria | 460169 | ⤷ Try a Trial | |||
| Austria | 9809 | ⤷ Try a Trial | |||
| Australia | 2004266050 | ⤷ Try a Trial | |||
| Australia | 2006313490 | ⤷ Try a Trial | |||
| Australia | 2009202429 | ⤷ Try a Trial | |||
| Brazil | PI0413394 | ⤷ Try a Trial | |||
| >Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |
